Contact
      Please use this form to send email to PR contact of this press release:
      
      Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes
    
      TO: